Research explained
CJC-1295 vs Mod GRF 1-29: DAC, No DAC & Evidence
The name CJC-1295 is used for different molecular forms. Start by checking whether the evidence concerns the long-acting DAC conjugate, then separate hormone measurements from clinical outcomes.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
Investigational research context. This guide provides no dosing schedule and does not treat different CJC-1295 forms as interchangeable.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| Teichman et al., 2006: long-acting CJC-1295 Randomized placebo-controlled studies in healthy adults | The study measured sustained changes in GH and IGF-1 after long-acting CJC-1295. | Hormone measurements are not evidence of improved symptoms or long-term clinical outcomes. |
| Ionescu and Frohman, 2006: GH pulsatility Hormone-sampling study in healthy men | Investigators examined GH secretion patterns following long-acting CJC-1295. | The study was not a sermorelin comparison or a trial of anti-aging outcomes. |
| FDA: CJC-1295-related substances briefing 2024 chemical and clinical review | The briefing distinguishes CJC-1295-related molecular forms, including the DAC conjugate. | Naming similarities do not establish identical molecular identity or interchangeable evidence. |
| FDA: CJC-1295 scientific review, December 2024 Chemical and pharmacological review | Separates DAC and non-DAC structures and cautions against extrapolating pharmacology between them. | A structural distinction does not establish a safe dose or a clinical benefit for either preparation. |
CJC-1295 DAC vs no DAC: start with identity
The FDA briefing distinguishes a DAC form with an added terminal conjugating unit from forms without it. Ask for the exact molecular identity in both the study and the product documentation before comparing results. A similar marketing name is insufficient.
Is CJC-1295 no DAC the same as Mod GRF 1-29?
Mod GRF 1-29 is commonly used for the modified 29-residue non-DAC analogue. FDA distinguishes a 29-amino-acid form from the DAC structure with its added terminal conjugating unit. Use the complete sequence, modification and salt specification to resolve a product label; do not rely on names being used consistently.
| Term | Distinction to verify | Evidence consequence |
|---|---|---|
| CJC-1295 with DAC | Added conjugating unit designed for albumin binding | Long-acting studies concern this structural context |
| No DAC / Mod GRF 1-29 | Modified 29-residue analogue without that unit | Do not transfer the DAC pharmacokinetic profile |
| Acetate or TFA | Salt/counterion description | A salt name does not tell you whether DAC is present |
Sources: FDA: CJC-1295-related substances briefing · FDA: CJC-1295 scientific review, December 2024
What does DAC change about the evidence?
The long-acting human studies linked above concern the compound developed for sustained exposure. Their findings cannot simply be assigned to another form. This distinction is especially relevant to internet half-life tables and claims about how long a product works.
What did the human studies establish?
The studies measured GH, IGF-1 and patterns of hormone secretion in healthy adults. They do not provide a head-to-head clinical comparison with sermorelin or prove adult wellness benefits. An endocrine response is a research finding, not a treatment recommendation.
How should a half-life claim be checked?
Match the molecular form, route, studied population and analyte. A hormone remaining elevated and a peptide remaining measurable are different observations. A useful citation must specify which one it describes.
What about CJC-1295 with ipamorelin?
A claim about a combination needs evidence for that combination and its intended outcome. Different signaling pathways can motivate research, but the studies listed here do not establish a combined protocol.
Common questions
Does no DAC mean the same result for a shorter time?
That interpretation is not established by a shared name. A different molecular form requires appropriate pharmacology and outcome evidence.
Can I use the long-acting study to set a dosing interval?
No dosing interval is recommended here. Research measurements in healthy adults do not establish an individual treatment plan.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.